首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   28480篇
  免费   2249篇
  国内免费   103篇
耳鼻咽喉   328篇
儿科学   818篇
妇产科学   485篇
基础医学   3268篇
口腔科学   695篇
临床医学   2974篇
内科学   6133篇
皮肤病学   531篇
神经病学   2757篇
特种医学   873篇
外国民族医学   2篇
外科学   4438篇
综合类   573篇
一般理论   26篇
预防医学   2315篇
眼科学   666篇
药学   2087篇
中国医学   39篇
肿瘤学   1824篇
  2022年   220篇
  2021年   496篇
  2020年   319篇
  2019年   485篇
  2018年   568篇
  2017年   408篇
  2016年   416篇
  2015年   527篇
  2014年   739篇
  2013年   1101篇
  2012年   1600篇
  2011年   1547篇
  2010年   927篇
  2009年   823篇
  2008年   1413篇
  2007年   1562篇
  2006年   1599篇
  2005年   1545篇
  2004年   1459篇
  2003年   1398篇
  2002年   1331篇
  2001年   515篇
  2000年   468篇
  1999年   506篇
  1998年   348篇
  1997年   299篇
  1996年   296篇
  1995年   246篇
  1994年   219篇
  1993年   208篇
  1992年   361篇
  1991年   306篇
  1990年   327篇
  1989年   261篇
  1988年   307篇
  1987年   274篇
  1986年   269篇
  1985年   262篇
  1984年   251篇
  1983年   250篇
  1982年   252篇
  1981年   236篇
  1980年   240篇
  1979年   246篇
  1978年   192篇
  1977年   156篇
  1976年   154篇
  1975年   156篇
  1974年   177篇
  1973年   162篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases.  相似文献   
4.
5.
6.
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.  相似文献   
7.
8.
9.
In this review we summarize the impact of the various modalities of breast cancer therapy coupled with intrinsic patient factors on incidence of subsequent treatment-induced myelodysplasia and acute myelogenous leukemia (t-MDS/AML). It is clear that risk is increased for patients treated with radiation and chemotherapy at younger ages. Radiation is associated with modest risk, whereas chemotherapy, particularly the combination of an alkylating agent and an anthracycline, carries higher risk and radiation and chemotherapy combined increase the risk markedly. Recently, treatment with granulocyte colony-stimulating factor (G-CSF), but not pegylated G-CSF, has been identified as a factor associated with increased t-MDS/AML risk. Two newly identified associations may link homologous DNA repair gene deficiency and poly (ADP-ribose) polymerase inhibitor treatment to increased t-MDS/AML risk. When predisposing factors, such as young age, are combined with an increasing number of potentially leukemogenic treatments that may not confer large risk singly, the risk of t-MDS/AML appears to increase. Patient and treatment factors combine to form a biological cascade that can trigger a myelodysplastic event. Patients with breast cancer are often exposed to many of these risk factors in the course of their treatment, and triple-negative patients, who are often younger and/or BRCA positive, are often exposed to all of them. It is important going forward to identify effective therapies without these adverse associated effects and choose existing therapies that minimize the risk of t-MDS/AML without sacrificing therapeutic gain.

Implications for Practice

Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.
  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号